ESTRO 2024 - Abstract Book

S1436

Clinical - Head & neck

ESTRO 2024

Ang, K Kian et al. “Human papillomavirus and survival of patients with oropharyngeal cancer.” The New England journal of medicine vol. 363,1 (2010): 24-35.

Chatterjee, S et al. "Intensifying Radiation Treatment in Advanced/Poor Prognosis Laryngeal, Hypopharyngeal (LH), and Oropharyngeal Cancers (OPC) Using PET – CT Based Dose Escalation Strategies — INTELHOPE." Journal-of Radiation-OncologyBiologyPhysics, vol. 99(2), 2017:E327-E328.

2933

Digital Poster

Utility of circulating tumor HPV DNA for oropharynx cancer treated at an urban medical center

Megi Gjini, Alla Ahmed, Christian Velten, Thomas J Ow, Bradley Schiff, Vikas Mehta, Enrico Castellucci, Madhur Garg, Rafi Kabarriti

Montefiore Medical Center, Radiation Oncology, Bronx NY, USA

Purpose/Objective:

To describe the utility of the blood-based test for circulating tumor tissue-modified viral (TTMV)-HPV DNA in a diverse patient population with HPV-mediated oropharynx squamous cell carcinoma.

Material/Methods:

This is a single-institution, retrospective study of 59 patients with at least one HPV ctDNA test using NavDx at Montefiore Medical Center between 2020 – 2023. Demographic and clinical outcomes data were collected. Pre treatment TTMV-DNA score was compared across different races and ethnicities using a one-way ANOVA test. The resulting plasma TTMV-DNA score was correlated with tumor volume and with AJCC 9th edition overall stage using Wilcoxon rank-sum test. The negative predictive value (NPV) of post-treatment TTMV-DNA fragment score was estimated for any recurrence and for no evidence of disease (NED).

Results:

The demographic and clinical data are summarized in Table 1. 29 patients had pre-treatment NavDx testing, of which 89.7% had detectable TTMV-DNA with a median score of 865 fragments/mL (range: 9 – 42,769). There was a strong positive association between detectable TTMV-DNA scores and both primary tumor volume (p <<< 0.01) and nodal volume (p <<< 0.01) with pre-treatment values. The association with overall stage was also significantly correlated to pre-treatment TTMV-HPV DNA (p = 0.00083). There was no significant difference between pre treatment TTMV-DNA scores and race or ethnicity (p = 0.97). The TTMV-DNA score for Non-Hispanic Black patients was 434.5 fragments/mL (range: 10 – 18,087); for Non-Hispanic White patients was 1,681 fragments/mL (range: 44 – 42,769); for Hispanic patients was 1,324 fragments (range: 865 – 4,574); and for Other patients was 1,227.5 fragments/mL (range: 9 – 24,618).